This PR today regarding K was necessary to reinfor
Post# of 72447
(Total Views: 429)
Posted On: 04/16/2019 11:34:15 AM
This PR today regarding K was necessary to reinforce to the medical community, and possible partners in particular, that IPIX is not a one trick pony consisting only of Brilacidin (though I don't see how Brilacidin alone could be considered a one trick pony with such a vast amount of possible indications)
I think it shows them that IPIX could have 2 monster drugs on their hands and thus not have to take any low ball offer for any indication. I agree with those that have remarked that currently we could have a bidding war heating up for OM. I would also hope it shows those bidding for OM that a low ball offer now will not look good on their resume should they try and bid on future indications or platforms. Time for them to step up to the plate is NOW.
I still do not see IBD or Kevetrin being in any partnership discussions as the value of each will rise dramatically upon the formulation of safe, effective pills.as a delivery system.
The PRs this year remind me of a baseball team loading up their minor league jsystem with outstanding prospects. Though they haven't contributed yet to the success of the parent company, in the near future they will combine to create a team that is unstoppable.
Makes one wonder how much other current research is ongoing regarding Kevetrin.
I think it shows them that IPIX could have 2 monster drugs on their hands and thus not have to take any low ball offer for any indication. I agree with those that have remarked that currently we could have a bidding war heating up for OM. I would also hope it shows those bidding for OM that a low ball offer now will not look good on their resume should they try and bid on future indications or platforms. Time for them to step up to the plate is NOW.
I still do not see IBD or Kevetrin being in any partnership discussions as the value of each will rise dramatically upon the formulation of safe, effective pills.as a delivery system.
The PRs this year remind me of a baseball team loading up their minor league jsystem with outstanding prospects. Though they haven't contributed yet to the success of the parent company, in the near future they will combine to create a team that is unstoppable.
Makes one wonder how much other current research is ongoing regarding Kevetrin.
(7)
(0)